Evidence map›Paper›PMID 40738679›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Adult T-cell Leukemia Following Satralizumab Treatment for Neuromyelitis Optica Spectrum Disorder.

Kenzo Sakurai, Yumi Ashikawa, Yoichiro Imaoka, Kumi Ohshima, Fumiaki Sano, Ayako Arai, Naoko Yagishita, Natsumi Araya, Makoto Nakashima, Erika Horibe and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kenzo SakuraiDepartment of Neurology, St. Marianna University School of Medicine, Japan.
Yumi AshikawaDepartment of Neurology, St. Marianna University School of Medicine, Japan.
Yoichiro ImaokaDepartment of Neurology, St. Marianna University School of Medicine, Japan.
Kumi OhshimaDepartment of Hematology and Oncology, St. Marianna University Graduate School of Medicine, Japan.
Fumiaki SanoDepartment of Hematology and Oncology, St. Marianna University Graduate School of Medicine, Japan.
Ayako AraiDepartment of Hematology and Oncology, St. Marianna University Graduate School of Medicine, Japan.
Naoko YagishitaDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan.
Natsumi ArayaDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan.
Makoto NakashimaDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan.
Erika HoribeDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan.
Tomoo SatoDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan.
Yoshihisa YamanoDepartment of Neurology, St. Marianna University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 78-year-old woman with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) developed acute-type adult T-cell leukemia (ATL) 1 month after initiating satralizumab, without prior human T-cell leukemia virus type 1 screening. She presented with respiratory symptoms and hematochezia after receiving three doses. Laboratory tests revealed abnormal lymphocytosis and HTLV-1 positivity, with monoclonal proliferation. Despite CHOP chemotherapy, the patient died within two weeks of treatment initiation. interleukin-6 inhibition may impair the host defense against HTLV-1 oncogenesis. This case highlights the potential risk of ATL following treatment with satralizumab, especially in HTLV-1 endemic areas, and the importance of HTLV-1 screening and clonality assessment before treatment in patients with NMOSD.

Indexed as

Antibodies, Monoclonal, HumanizedLeukemia-Lymphoma, Adult T-CellNeuromyelitis OpticaAgedFatal OutcomeFemaleHumansHuman T-lymphotropic virus 1Antibodies, Monoclonal, Humanizedadult T-cell leukemiaclonalityHTLV-1interleukin-6neuromyelitis optica spectrum disordersatralizumab

Identifiers

PMID40738679
PMCPMC13019010

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.